Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

• Asıl Yazarlar: Westerhout KY (Yazar), Bouwmeester W (Yazar), Duchesne I (Yazar), Pisini M (Yazar), Piena MA (Yazar), Damele F (Yazar), Gueron B (Yazar), Treur M (Yazar), Belsey J (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Dove Medical Press, 2017-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg, Beerse, Belgium; 3Janssen-Cilag SpA, Via Michel...